Autoimmune dementia and encephalopathy

Research output: Chapter in Book/Report/Conference proceedingConference contribution

7 Citations (Scopus)

Abstract

Autoimmune dementia and encephalopathies (ADE) are complex disorders that can cause immune-mediated cognitive deficits and have confusing nomenclature. Presentation varies from acute limbic encephalitis to subacute or chronic disorders of cognition mimicking neurodegenerative dementia. It may occur as a paraneoplastic phenomenon or an idiopathic autoimmune phenomenon. The presence of a personal/family history of autoimmunity, inflammatory spinal fluid, serologic evidence of autoimmunity (neural or nonorgan-specific), or mesial temporal magnetic resonance imaging abnormalities are clues to diagnosis. Bedside cognitive assessment and/or detailed neuropsychologic testing are useful. Neural-specific autoantibodies, mostly discovered in the past two decades, may bind antigens on the cell surface (e.g., N-methyl-. d-aspartate receptor autoantibodies) and are likely to be pathogenic, with treatment aimed at antibody-depleting agents often with success, while antibodies binding intracellular antigens (e.g., antineuronal nuclear autoantibody type 1 (ANNA1 or anti-Hu)) are a marker of a T-cell-mediated process and treated with T-cell-depleting immunotherapies, with variable responses. Detection and treatment of cancer (when present) are essential. High-dose corticosteroids are the initial treatment in most patients and may serve as a diagnostic test when the diagnosis is uncertain. Repeat cognitive testing after immunotherapy helps document objective improvements. Maintenance immunotherapy is recommended in those at risk for relapse. Prognosis is variable, but paraneoplastic ADE with antibodies to intracellular antigens have a worse prognosis. The field is still developing and future studies should provide guidelines for diagnosis and treatments.

Original languageEnglish (US)
Title of host publicationAutoimmune Neurology, 2016
PublisherElsevier
Pages247-267
Number of pages21
Volume133
ISBN (Print)9780444634320
DOIs
StatePublished - 2016

Publication series

NameHandbook of Clinical Neurology
Volume133
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Brain Diseases
Dementia
Autoantibodies
Immunotherapy
Autoimmunity
Antibodies
Cognition Disorders
Limbic Encephalitis
T-Lymphocytes
Antigens
Therapeutics
Surface Antigens
Routine Diagnostic Tests
Terminology
Adrenal Cortex Hormones
Maintenance
Magnetic Resonance Imaging
Guidelines
Recurrence
Neoplasms

Keywords

  • Hashimoto's encephalopathy
  • NMDA receptor encephalitis
  • Nonvasculitic autoimmune inflammatory meningoencephalitis
  • Paraneoplastic encephalitis
  • Progressive encephalomyelitis rigidity and myoclonus
  • Steroid-responsive encephalopathy associated with autoimmune thyroiditis
  • Voltage-gated potassium channel complex

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Flanagan, E., Drubach, D., & Boeve, B. F. (2016). Autoimmune dementia and encephalopathy. In Autoimmune Neurology, 2016 (Vol. 133, pp. 247-267). (Handbook of Clinical Neurology; Vol. 133). Elsevier. https://doi.org/10.1016/B978-0-444-63432-0.00014-1

Autoimmune dementia and encephalopathy. / Flanagan, Eoin; Drubach, Daniel; Boeve, Bradley F.

Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. p. 247-267 (Handbook of Clinical Neurology; Vol. 133).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Flanagan, E, Drubach, D & Boeve, BF 2016, Autoimmune dementia and encephalopathy. in Autoimmune Neurology, 2016. vol. 133, Handbook of Clinical Neurology, vol. 133, Elsevier, pp. 247-267. https://doi.org/10.1016/B978-0-444-63432-0.00014-1
Flanagan E, Drubach D, Boeve BF. Autoimmune dementia and encephalopathy. In Autoimmune Neurology, 2016. Vol. 133. Elsevier. 2016. p. 247-267. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-444-63432-0.00014-1
Flanagan, Eoin ; Drubach, Daniel ; Boeve, Bradley F. / Autoimmune dementia and encephalopathy. Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. pp. 247-267 (Handbook of Clinical Neurology).
@inproceedings{f62bb870f59241eaba45343b58bf9abc,
title = "Autoimmune dementia and encephalopathy",
abstract = "Autoimmune dementia and encephalopathies (ADE) are complex disorders that can cause immune-mediated cognitive deficits and have confusing nomenclature. Presentation varies from acute limbic encephalitis to subacute or chronic disorders of cognition mimicking neurodegenerative dementia. It may occur as a paraneoplastic phenomenon or an idiopathic autoimmune phenomenon. The presence of a personal/family history of autoimmunity, inflammatory spinal fluid, serologic evidence of autoimmunity (neural or nonorgan-specific), or mesial temporal magnetic resonance imaging abnormalities are clues to diagnosis. Bedside cognitive assessment and/or detailed neuropsychologic testing are useful. Neural-specific autoantibodies, mostly discovered in the past two decades, may bind antigens on the cell surface (e.g., N-methyl-. d-aspartate receptor autoantibodies) and are likely to be pathogenic, with treatment aimed at antibody-depleting agents often with success, while antibodies binding intracellular antigens (e.g., antineuronal nuclear autoantibody type 1 (ANNA1 or anti-Hu)) are a marker of a T-cell-mediated process and treated with T-cell-depleting immunotherapies, with variable responses. Detection and treatment of cancer (when present) are essential. High-dose corticosteroids are the initial treatment in most patients and may serve as a diagnostic test when the diagnosis is uncertain. Repeat cognitive testing after immunotherapy helps document objective improvements. Maintenance immunotherapy is recommended in those at risk for relapse. Prognosis is variable, but paraneoplastic ADE with antibodies to intracellular antigens have a worse prognosis. The field is still developing and future studies should provide guidelines for diagnosis and treatments.",
keywords = "Hashimoto's encephalopathy, NMDA receptor encephalitis, Nonvasculitic autoimmune inflammatory meningoencephalitis, Paraneoplastic encephalitis, Progressive encephalomyelitis rigidity and myoclonus, Steroid-responsive encephalopathy associated with autoimmune thyroiditis, Voltage-gated potassium channel complex",
author = "Eoin Flanagan and Daniel Drubach and Boeve, {Bradley F}",
year = "2016",
doi = "10.1016/B978-0-444-63432-0.00014-1",
language = "English (US)",
isbn = "9780444634320",
volume = "133",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "247--267",
booktitle = "Autoimmune Neurology, 2016",

}

TY - GEN

T1 - Autoimmune dementia and encephalopathy

AU - Flanagan, Eoin

AU - Drubach, Daniel

AU - Boeve, Bradley F

PY - 2016

Y1 - 2016

N2 - Autoimmune dementia and encephalopathies (ADE) are complex disorders that can cause immune-mediated cognitive deficits and have confusing nomenclature. Presentation varies from acute limbic encephalitis to subacute or chronic disorders of cognition mimicking neurodegenerative dementia. It may occur as a paraneoplastic phenomenon or an idiopathic autoimmune phenomenon. The presence of a personal/family history of autoimmunity, inflammatory spinal fluid, serologic evidence of autoimmunity (neural or nonorgan-specific), or mesial temporal magnetic resonance imaging abnormalities are clues to diagnosis. Bedside cognitive assessment and/or detailed neuropsychologic testing are useful. Neural-specific autoantibodies, mostly discovered in the past two decades, may bind antigens on the cell surface (e.g., N-methyl-. d-aspartate receptor autoantibodies) and are likely to be pathogenic, with treatment aimed at antibody-depleting agents often with success, while antibodies binding intracellular antigens (e.g., antineuronal nuclear autoantibody type 1 (ANNA1 or anti-Hu)) are a marker of a T-cell-mediated process and treated with T-cell-depleting immunotherapies, with variable responses. Detection and treatment of cancer (when present) are essential. High-dose corticosteroids are the initial treatment in most patients and may serve as a diagnostic test when the diagnosis is uncertain. Repeat cognitive testing after immunotherapy helps document objective improvements. Maintenance immunotherapy is recommended in those at risk for relapse. Prognosis is variable, but paraneoplastic ADE with antibodies to intracellular antigens have a worse prognosis. The field is still developing and future studies should provide guidelines for diagnosis and treatments.

AB - Autoimmune dementia and encephalopathies (ADE) are complex disorders that can cause immune-mediated cognitive deficits and have confusing nomenclature. Presentation varies from acute limbic encephalitis to subacute or chronic disorders of cognition mimicking neurodegenerative dementia. It may occur as a paraneoplastic phenomenon or an idiopathic autoimmune phenomenon. The presence of a personal/family history of autoimmunity, inflammatory spinal fluid, serologic evidence of autoimmunity (neural or nonorgan-specific), or mesial temporal magnetic resonance imaging abnormalities are clues to diagnosis. Bedside cognitive assessment and/or detailed neuropsychologic testing are useful. Neural-specific autoantibodies, mostly discovered in the past two decades, may bind antigens on the cell surface (e.g., N-methyl-. d-aspartate receptor autoantibodies) and are likely to be pathogenic, with treatment aimed at antibody-depleting agents often with success, while antibodies binding intracellular antigens (e.g., antineuronal nuclear autoantibody type 1 (ANNA1 or anti-Hu)) are a marker of a T-cell-mediated process and treated with T-cell-depleting immunotherapies, with variable responses. Detection and treatment of cancer (when present) are essential. High-dose corticosteroids are the initial treatment in most patients and may serve as a diagnostic test when the diagnosis is uncertain. Repeat cognitive testing after immunotherapy helps document objective improvements. Maintenance immunotherapy is recommended in those at risk for relapse. Prognosis is variable, but paraneoplastic ADE with antibodies to intracellular antigens have a worse prognosis. The field is still developing and future studies should provide guidelines for diagnosis and treatments.

KW - Hashimoto's encephalopathy

KW - NMDA receptor encephalitis

KW - Nonvasculitic autoimmune inflammatory meningoencephalitis

KW - Paraneoplastic encephalitis

KW - Progressive encephalomyelitis rigidity and myoclonus

KW - Steroid-responsive encephalopathy associated with autoimmune thyroiditis

KW - Voltage-gated potassium channel complex

UR - http://www.scopus.com/inward/record.url?scp=84978437407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978437407&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63432-0.00014-1

DO - 10.1016/B978-0-444-63432-0.00014-1

M3 - Conference contribution

C2 - 27112681

AN - SCOPUS:84978437407

SN - 9780444634320

VL - 133

T3 - Handbook of Clinical Neurology

SP - 247

EP - 267

BT - Autoimmune Neurology, 2016

PB - Elsevier

ER -